119618-22-3

Usage

Chemical Properties

Off-White Solid

InChI:InChI=1/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m0/s1

Upstream product

• 1508-65-2 Oxybutynin chloride 
• 22396-77-6 acetic acid-(4-diethylamino-but-2-ynyl ester) 
• 10399-13-0 methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate 
• 10575-25-4 4-diethylamino-2-butyn-1-ol 
• 4335-77-7 cyclohexylmandelic acid 

Downstream Products

• 1508-65-2 Oxybutynin chloride 
• 80976-67-6 4-(ethylamino)-2-butynyl α-cyclohexyl-α-hydroxybenzeneacetate 
• 688364-67-2 4-(diethylmethylaminium)-2-butynyl alpha phenyl cyclohexane glycolate iodide 
• 10575-25-4 4-diethylamino-2-butyn-1-ol 
• 4335-77-7 cyclohexylmandelic acid 

Relevant academic research and scientific papers

POLYMORPHIC FORMS OF (R)-OXYBUTYNIN HYDROCHLORIDE

Polymorphic forms of (R)-oxybutynin HC1, including three crystalline forms, are prepared and characterized. Uses of the various polymorphic forms of (R)-oxybutynin HC1 for Obstructive Sleep Apnea (OS A) treatment are also disclosed.

CRYSTALLINE OXYBUTYNIN AND PROCESS FOR PREPARING THE SAME

The present invention relates to a crystalline oxybutynin base and process for preparing the same. Further, this invention discloses a process for preparing an acid addition salt of oxybutynin employing the crystalline oxybutynin base.

SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES

Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY

Systems and methods for treating diseases, addictions and disorders in humans and animals involving synchronizing and tailoring the administration of drug compounds with the body's natural circadian rhythms, in order to counteract symptoms when they are likely to be at their worst. Automated and pre programmable transdermal drug administration system are used. This system can also utilize a pump or pressurized reservoir, and/or a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with micro-fabricated structures commonly referred to as Micro-needles, or heat, or iontophoresis, sonophoresis, or a wide range of chemical permeation enhancers.

QUATERNARY AMMONIUM COMPOUNDS

The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.